These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Collagen copolymer toric posterior chamber phakic intraocular lenses to correct high myopic astigmatism.
    Author: Alfonso JF, Baamonde B, Madrid-Costa D, Fernandes P, Jorge J, Montés-Micó R.
    Journal: J Cataract Refract Surg; 2010 Aug; 36(8):1349-57. PubMed ID: 20656159.
    Abstract:
    PURPOSE: To assess the safety, efficacy, stability, and predictability after implantation of a toric intraocular copolymer (Collamer) lens (pIOL) to correct high myopic astigmatism. SETTING: Fernández-Vega Ophthalmological Institute, Oviedo, Spain. METHODS: This study evaluated eyes that had implantation of a toric pIOL. Outcome measures were the uncorrected (UDVA) and corrected (CDVA) distance visual acuities (Snellen decimal), refraction, and postoperative complications. RESULTS: The study included 15 eyes of 12 patients (9 women). Preoperatively, the mean manifest spherical refraction was -1.98 diopters (D) +/- 1.32 (SD) (range -0.50 to -5.50 D) and the mean refractive cylinder, -4.85 +/- 0.83 D (range -6.50 to -4.00 D). At 12 months, the mean refractive cylinder was -0.55 +/- 0.52 D (range -1.50 to 0.00 D), with 93.3% of eyes having less than 1.00 D of cylinder. The mean spherical equivalent was -0.31 +/- 0.42 (range -1.00 to 0.75 D), with more than 70% of eyes within +/-0.50 D of the target. For the astigmatic components, 93.3% of eyes were within +/-1.00 D of J0 (r(2) = 0.98) and all eyes were within +/-1.00 D of J45 (r(2) = 0.98). The mean UDVA was 0.70 +/- 0.20 and the mean CDVA, 0.83 +/- 0.12. The overall efficacy index was 0.90. Postoperatively, all eyes had unchanged CDVA or gained 1 or more lines. CONCLUSION: The refractive outcomes and improvement in UDVA and CDVA were rapidly achieved and remained fairly consistent throughout the follow-up period, supporting the use of toric pIOLs in eyes with high astigmatism. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned.
    [Abstract] [Full Text] [Related] [New Search]